New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 3, 2014
06:24 EDTPGNXProgenics upgraded to Buy from Hold at Needham
Needham upgraded Progenics Pharmaceuticals with an $8 price target citing the company's positive Phase 2 data for prostate cancer.
News For PGNX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 1, 2015
10:16 EDTPGNXProgenics management to meet with Brean Capital
Meetings to be held in Chicago on May 7 and in San Francisco on May 8 hosted by Brean Capital.
April 24, 2015
09:18 EDTPGNXValeant and Progenics' Relistor eceives positive opinion from EMA
Valeant (VRX) and Progenics (PGNX) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending a new indication for Relistor Subcutaneous Injection for the treatment of opioid-induced constipation when response to laxative therapy has not been sufficient in adult patients, aged 18 years and older. Additionally, the Committee has recommended a one-year extension of data/marketing protection for Relistor, to 11 years from the date of approval.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use